NOW APPROVED

Coming soon to a pharmacy near you

NOCDURNA, the first and only sublingual tablet for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.1

When treating patients with nocturia due to nocturnal polyuria (NP), prescribe the MELT:

MINUTES

Sublingual tablet dissolves rapidly and starts working in minutes1*

*Onset of antidiuretic action occurs within 30 minutes.

EFFECTIVE

NOCDURNA has demonstrated a reduction in nighttime voids (the number of times patients wake to urinate)1

LONG­STUDIED

Years of clinical trial experience1

TARGETED

Treats the overproduction of urine at night, by targeting the kidneys with specific dosing for men and women1

Clinical trials demonstrated a reduction of 1.5 nocturnal voids in women (n=118) and 1.3 nocturnal voids in men (n=102) relative to mean baseline. (The mean baseline was 2.9 for women and 3.0 for men.) 78% of women and 67% of men achieved a 33% reduction in mean number of nocturnal voids over a 3-month period compared to baseline.1

If you are a patient, ask your doctor if NOCDURNA is right for you.

Thank you, but you’re not currently eligible for the Early Experience Program.

Thank you, but you’re not currently eligible for the Early Experience Program. You’ll receive news and updates about NOCDURNA.

Thank you for signing up. Please remember to print out and send back the fax-back form. We’ll be in touch regarding your Early Experience kit.

Thank you for signing up. Please remember to print out and send back the fax-back form. We’ll be in touch regarding your Early Experience kit. You’ll also receive news and updates about NOCDURNA.

Thank you, you’ll receive news and updates about NOCDURNA.

For Healthcare Professionals Only

The NOCDURNA Early Experience Program

The Early Experience Program is designed to give doctors an opportunity to try NOCDURNA in adults with nocturia due to nocturnal polyuria (NP) who awaken at least 2 times per night to void. HCPs enrolled in the program will receive a package of patient kits including product samples and materials to track patient progress on NOCDURNA. Due to limited enrollment time, not all physicians will be able to participate.

Enter your NPI number to enroll in the Early Experience Program and/or receive news and updates about NOCDURNA.

Once enrolled, you will receive a confirmation email with further details.

Please select one or both

All fields are required unless otherwise noted.

By providing the information requested, I authorize Ferring to enter the information I have provided into a database. I agree that Ferring, its agents, subcontractors, affiliates, or third parties under contract with them may contact me from time to time by telephone, mail, or email to provide information about products or services that may be of interest to me. I understand that the information will be treated confidentially and will be accessed only by authorized personnel or third parties under contract with Ferring or its affiliates. I have a right of access and verification to my personal information. I also have a right to opt out of the database at any time. Subject to the above, unless authorized by me, my personal information will not be sold or transferred to third parties, other than in the event of Ferring or its affiliates being sold. If you no longer wish to receive such communications from Ferring, you may “opt out” at any time by calling Ferring at 1-888-FERRING, Monday through Friday, 8:00 a.m. to 7:00 p.m. EST to speak to a representative or leave a voicemail. This statement may be updated from time to time.

INDICATION AND IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

INDICATION

NOCDURNA is a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.

IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

WARNING: HYPONATREMIA

See full Prescribing Information for complete boxed warning

  • NOCDURNA can cause hyponatremia, which may be life-threatening if severe.
  • NOCDURNA is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids.
  • Ensure serum sodium concentration is normal before starting or resuming NOCDURNA. Measure serum sodium within 1 week and approximately 1 month after initiating therapy and periodically during treatment. More frequently monitor serum sodium in patients 65 years of age and older and in patients at increased risk of hyponatremia.
  • If hyponatremia occurs, NOCDURNA may need to be temporarily or permanently discontinued.

CONTRAINDICATIONS

  • Hyponatremia or a history of hyponatremia
  • Polydipsia
  • Concomitant use with loop diuretics or systemic or inhaled glucocorticoids
  • Estimated glomerular filtration rate below 50 mL/min/1.73 m2
  • Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
  • During illnesses that can cause fluid or electrolyte imbalance
  • Heart failure
  • Uncontrolled hypertension

WARNINGS AND PRECAUTIONS

  • Limit fluid intake to a minimum from 1 hour before until 8 hours after administration. Treatment without concomitant reduction of fluid intake may lead to fluid retention and hyponatremia.
  • Fluid retention: Not recommended in patients at risk of increased intracranial pressure or history of urinary retention.

ADVERSE REACTIONS

Common adverse reactions (>2% incidence) included dry mouth, hyponatremia or blood sodium decreased, and dizziness.

DRUG INTERACTIONS

Monitor serum sodium more frequently when NOCDURNA is concomitantly used with drugs that may increase the risk of hyponatremia (e.g. tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, carbamazepine, lamotrigine, sulfonylureas, particularly chlorpropamide and NSAIDS).

USE IN SPECIFIC POPULATIONS

Pregnancy: Use of NOCDURNA is not recommended.

Geriatric Use: Increased risk of hyponatremia if 65 years of age or older. Monitor serum sodium more frequently.

To report SUSPECTED ADVERSE REACTIONS, contact Ferring at 1-888-337-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information, including BOXED WARNING, and Medication Guide.

 

Reference: 1. NOCDURNA [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.